Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Tracheal Diseases 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Fulvestrant 127Trastuzumab 117Paclitaxel 113Letrozole 109pembrolizumab 81palbociclib 76pertuzumab 75Capecitabine 74Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 57Specimen Handling 51Surveys and Questionnaires 50Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 42olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Combined Modality Therapy × 1 year × Clear all
NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡